Post-modern Medicolegal and Forensic Toxicology

  • Hans H. Maurer


The ongoing progress in analytical and life sciences is opening up new perspectives in post-modern medico-legal and forensic toxicology. In times of personalized medicine, the interpretation of analytical results in clinical and forensic cases should also be based on genetic aspects, pharmacogenomics in particular. Pharmacologic and toxic effects of drugs or poisons may be influenced by the genotype and phenotype of an individual, but also by the isoenzymes involved in their metabolism and membrane transport. Further individual factors such as body mass, age, sex, kidney and liver function, and drug-drug (food-drug) interactions may have an impact. Detailed knowledge of all these factors is a prerequisite for evidence-based case interpretation. In this chapter, the current knowledge of possible risks in variations of the effects of relevant therapeutic drugs, herbal drugs, and drugs of abuse will be presented. A critical discussion of the impact on the interpretation of analytical results in clinical and forensic toxicology will follow.


  1. 1.
    Meyer MR, Helfer AG, Maurer HH (2014) Current position of high-resolution mass spectrometry for drug quantification in clinical & forensic toxicology. Bioanalysis 6:2275–2284CrossRefPubMedGoogle Scholar
  2. 2.
    Maurer HH, Meyer MR (2016) High-resolution mass spectrometry in toxicology—current status and future perspectives. Arch Toxicol 90(9):2161–2172CrossRefPubMedGoogle Scholar
  3. 3.
    Wille SMR, Peters FT, Di Fazio V, Samyn N (2011) Practical aspects concerning validation and quality control for forensic and clinical bioanalytical quantitative methods. Accred Qual Assur 16:279–292CrossRefGoogle Scholar
  4. 4.
    Schulz M, Iwersen-Bergmann S, Andresen H, Schmoldt A (2012) Therapeutic and toxic blood concentrations of nearly 1000 drugs and other xenobiotics. Crit Care 16:R136CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Bengtsson F (2004) Therapeutic drug monitoring of psychotropic drugs. Ther Drug Monit 26:145–151CrossRefPubMedGoogle Scholar
  6. 6.
    Maurer HH (2007) Demands on scientific studies in clinical toxicology. Forensic Sci Int 165:194–198CrossRefPubMedGoogle Scholar
  7. 7.
    Schwab M, Schaeffeler E (2012) Pharmacogenomics: a key component of personalized therapy. Genome Med 4:93CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Meyer UA, Zanger UM, Schwab M (2013) Omics and drug response. Annu Rev Pharmacol Toxicol 53:475–502CrossRefPubMedGoogle Scholar
  9. 9.
    Wong SH, Happy C, Blinka D et al (2010) From personalized medicine to personalized justice: the promises of translational pharmacogenomics in the justice system. Pharmacogenomics 11:731–737CrossRefPubMedGoogle Scholar
  10. 10.
    Kalow W (2006) Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine. Pharmacogenomics J 6:162–165CrossRefPubMedGoogle Scholar
  11. 11.
    Sim SC, Ingelman-Sundberg M (2011) Pharmacogenomic biomarkers: new tools in current and future drug therapy. Trends Pharmacol Sci 32:72–81CrossRefPubMedGoogle Scholar
  12. 12.
    Maurer HH (2010) Chemistry, Pharmacology, and Metabolism of Emerging Drugs of Abuse. Ther Drug Monit 32:544–549CrossRefPubMedGoogle Scholar
  13. 13.
    Meyer MR, Maurer HH (2012) Current status of hyphenated mass spectrometry in studies of the metabolism of drugs of abuse, including doping agents. Anal Bioanal Chem 402:195–208CrossRefPubMedGoogle Scholar
  14. 14.
    Meyer MR, Richter LHR, Maurer HH (2014) Methylenedioxy designer drugs: mass spectrometric characterization of their glutathione conjugates by means of liquid chromatography-high-resolution mass spectrometry/mass spectrometry and studies on their glutathionyl transferase inhibition potency. Anal Chim Acta 822:37–50CrossRefPubMedGoogle Scholar
  15. 15.
    Meyer MR, Robert A, Maurer HH (2014) Toxicokinetics of novel psychoactive substances: Characterization of N-acetyltransferase (NAT) isoenzymes involved in the phase II metabolism of 2C designer drugs. Toxicol Lett 227:124–128CrossRefPubMedGoogle Scholar
  16. 16.
    Meyer MR, Schütz A, Maurer HH (2014) Contribution of human esterases to the metabolism of selected drugs of abuse. Toxicol Lett 232:159–166CrossRefPubMedGoogle Scholar
  17. 17.
    Welter-Luedeke J, Maurer HH (2015) New psychoactive substances: chemistry, pharmacology, metabolism, and detectability of amphetamine derivatives with modified ring systems. Ther Drug Monit 38:4–11CrossRefGoogle Scholar
  18. 18.
    Schaefer N, Wojtyniak JG, Kettner M et al (2016) Pharmacokinetics of (synthetic) cannabinoids in pigs and their relevance for clinical and forensic toxicology. Toxicol Lett 253:7–16CrossRefPubMedGoogle Scholar
  19. 19.
    Richter LHR, Kaminski YR, Noor F, Meyer MR, Maurer HH (2016) Metabolic fate of desomorphine elucidated using rat urine, pooled human liver preparations, and human hepatocyte cultures as well as its detectability using standard urine screening approaches. Anal Bioanal Chem 408:6283−6294Google Scholar
  20. 20.
    Wagmann L, Meyer MR, Maurer HH (2016) What is the contribution of human FMO3 in the N-oxygenation of selected therapeutic drugs and drugs of abuse? Toxicol Lett 258:70CrossRefGoogle Scholar
  21. 21.
    Dinger J, Meyer MR, Maurer HH (2016) In vitro cytochrome P450 inhibition potential of methylenedioxy-derived designer drugs studied with a two cocktail approach. Arch Toxicol 90:305–318CrossRefPubMedGoogle Scholar
  22. 22.
    Dinger J, Woods C, Brandt SD, Meyer MR, Maurer HH (2016) Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicol Lett 241:82–94CrossRefPubMedGoogle Scholar
  23. 23.
    Meyer MR, Wagmann L, Schneider-Daum N, Loretz B, de Souza-Carvalho C, Lehr CM, Maurer HH (2015) P-glycoprotein interactions of novel psychoactive substances - stimulation of ATP consumption and transport across Caco-2 monolayers. Biochem Pharmacol 94:220–226CrossRefPubMedGoogle Scholar
  24. 24.
    Kitamura S, Maeda K, Sugiyama Y (2008) Recent progresses in the experimental methods and evaluation strategies of transporter functions for the prediction of the pharmacokinetics in humans. Naunyn Schmiedebergs Arch Pharmacol 377:617–628CrossRefPubMedGoogle Scholar
  25. 25.
    Wilson AGE (ed) (2016) New Horizons in Predictive Drug Metabolism and Pharmacokinetics. Royal Society of Chemistry, LondonGoogle Scholar
  26. 26.
    Stamer UM, Zhang L, Stuber F (2010) Personalized therapy in pain management: where do we stand? Pharmacogenomics 11:843–864CrossRefPubMedGoogle Scholar
  27. 27.
    Lee HK, Lewis LD, Tsongalis GJ, McMullin M, Schur BC, Wong SH, Yeo KT (2006) Negative urine opioid screening caused by rifampin-mediated induction of oxycodone hepatic metabolism. Clin Chim Acta 367:196–200CrossRefPubMedGoogle Scholar
  28. 28.
    Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J (2004) Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 351:2827–2831CrossRefPubMedGoogle Scholar
  29. 29.
    Ghassabian S, Chetty M, Tattam BN et al (2009) A high-throughput assay using liquid chromatography-tandem mass spectrometry for simultaneous in vivo phenotyping of 5 major cytochrome p450 enzymes in patients. Ther Drug Monit 31:239–246CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2017

Authors and Affiliations

  1. 1.Department of Experimental and Clinical ToxicologySaarland UniversityHomburg, SaarGermany

Personalised recommendations